Navigation Links
Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
Date:5/28/2009

on December 15, 2008. The FDA has assigned a PDUFA date of July 30, 2009 to the Intermezzo(R) NDA.

For further information, please visit the company's website at: www.transcept.com.

Forward Looking Statements

This press release contains forward looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the ability of merger proceeds to be sufficient to carry out its plans to commercialize Intermezzo(R); and the potential for Intermezzo(R) to receive timely FDA approval and be the first commercially available sleep aid specifically designed for use in the middle of the night. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, delays in FDA approval of Intermezzo(R); unanticipated additional expenses in connection with the commercialization of Intermezzo(R), if approved; Transcept product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of Transcept product candidates.

    Contacts:
    Transcept Pharmaceuticals, Inc.     
'/>"/>
SOURCE  Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 

Related medicine news :

1. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
2. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
3. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
4. Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
5. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
6. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
7. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
8. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
9. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
10. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... AquaPrint Solutions in Thomson, IL is proud to ... newly-designed Harley Davidson motorcycle gas tank. A couple of weeks ... idea of taking a split tank motorcycle that had been ... into a work of art. , In October of ... seats that had been dipped in a water transfer printer ...
(Date:6/19/2013)... 2013 Ethigen announced today the US ... service , providing next-generation sequencing (NGS) and rearrangement analysis ... part of an expanded hereditary cancer panel, including full ... links to cancer risk: MLH1, MSH2, MSH6, APC, MUTYH ... FH, FLCN, PDGFRA, and KIT. , The expanded ...
(Date:6/19/2013)... When looking for ways to lose weight ... how to lose belly fat and excess fat in other ... Unnecessary and excess fat storage in these areas can be ... created their hCG diets to specially address these ... loss aids with nutritious meal plans and education on healthy ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Walkingspree, a ... today announced the launch of its new Facebook App. ... motivate and inspire participants to reach their program fitness ... platform , Walkingspree clients are given more tools to ... member profile. , Corporate clients may choose whether or ...
(Date:6/19/2013)... The website HealthNewsWires.com has recently published an informative article ... tips to manage and prevent the condition. , In ... defines insulin resistance as a condition that ... from the bloodstream. Glucose, or blood sugar, is ... systems of the body for normal function. The ...
Breaking Medicine News(10 mins):Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2Health News:Ethigen Launches Next Generation (NGS) BRCA Testing With Expanded Hereditary Cancer Panel 2Health News:Ethigen Launches Next Generation (NGS) BRCA Testing With Expanded Hereditary Cancer Panel 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce A New Four Phase Program that Allows Patients to Lose Belly Fat, Thigh Fat and Underarm Fat Easily 2Health News:Walkingspree’s New Facebook Connectivity Boosts Accountability and Engagement 2Health News:Effects of Insulin Resistance and How to Increase Insulin Sensitivity Published in New Video by Health News Wire 2
... highlighted that patients who receive a hematopoietic stem cell transplant ... especially// if they are older during the time of the ... ,A peer-reviewed journal of the American Cancer ... allogeneic HSCT, the comparative risk of a second cancer is ...
... British government has been investing millions of pounds into ... to conduct a massive survey to determine how// accessible ... the intended survey, patients are going to be endowed ... contributing to the doctor’s income. ,The Prime Minister ...
... has planned to kill cats and dogs over fears of ... cull even dogs and cats so as to prevent further ... deadly H5N1 virus at a chicken farm last week. Animal ... extreme measure' because there was no scientific evidence that cats ...
... According to a new study published in January ... short-term structural changes in the cognitive areas of ... journal of the American Cancer Society, the researchers ... months of receiving adjuvant chemotherapy, significant regions of ...
... have observed an alarming trend in the kids, even those between ... teenagers. The physical and// behavioral changes which marks the teenage years ... of 8 to 12; so the sobriquet ‘tweens’, seems to fit ... fancy to own expensive items like cell phones and iPods. The ...
... in Australia to study the attitudes of people towards “tissue ... concerned about the// outcome of storage of tissue samples at ... found that ,most people were wary about biopsy tissue being ... possibly be used to produce human clones in the future. ...
Cached Medicine News:Health News:Stem cell transplant recipients face significant risk of second cancer 2Health News:Britons soon will practise telling GPs how to practice 2Health News:Banking (T)issues : cloning issue surfaces 2
(Date:6/19/2013)... , June 19, 2013 /PRNewswire-iReach/ -- ... a new specialty pharmaceutical company dedicated to ... innovative injectable and sustained release drug therapies ... medical needs, today announced the acquisition of ... Technology®) platform and associated product pipeline. Acquisition ...
(Date:6/19/2013)... YORK , June 19, 2013 ... brand new infographic summary of the results from ... a third of all respondents stated that CROs would be ... 50% of respondents will be running 6 or more clinical ... with the Clinical Trial Supply USA ...
(Date:6/18/2013)... Valeant Pharmaceuticals International, Inc. (NYSE: ... that VPII Escrow Corp., a newly formed wholly owned ... of approximately $3.2 billion aggregate principal amount of senior ... in 2021 and in 2023, with final tranching determined ... the net proceeds from the offering, together with proceeds ...
Breaking Medicine Technology:Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: